Citius Pharmaceuticals, Inc. (CTXR) - Dilution Analysis

10-Q filing | 27.5M shares outstanding

8-K filing: Citius Pharmaceuticals, Inc. entered into a securities purchase agreement for the issuance and sale of common stock and warrants in a registered direct offering and concurrent private placement, resulting in gross proceeds of approximately $5.0 million.

10-K filing | 20.8M shares outstanding

8-K filing: Citius Pharmaceuticals, Inc. issued 1,460,000 shares of common stock and pre-funded warrants to purchase up to 2,513,510 shares in a registered direct offering that closed on October 21, 2025. ($6.0M proceeds)

10-Q filing | 17.0M shares outstanding

8-K filing: Citius Pharmaceuticals, Inc. entered into a securities purchase agreement for the issuance and sale of 540,000 shares of common stock and pre-funded warrants to purchase up to 4,380,000 shares of common stock at an offering price of $1.22 and $1.2199, respectively, along with warrants to purchase up to 9,840,000 shares of common stock, in a registered direct offering that closed on June 11, 2025. ($0.0M proceeds)

10-Q filing | 10.3M shares outstanding

8-K filing: Citius Pharmaceuticals, Inc. entered into a securities purchase agreement for the issuance and sale of 465,000 shares of common stock and pre-funded warrants to purchase up to 1,274,131 shares at $1.15 and $1.1499, respectively, which closed on April 2, 2025.

10-Q filing | 8.6M shares outstanding

8-K filing: Citius Pharmaceuticals, Inc. entered into a securities purchase agreement for the issuance and sale of 743,496 shares of common stock and warrants at a combined offering price of $4.035, which closed on January 8, 2025. ($3.0M proceeds)

10-K filing | 7.7M shares outstanding

8-K filing: Stock split 1-for-25 | Outstanding: 173,856,960 → 6,954,278

8-K filing: Citius Pharmaceuticals, Inc. completed a registered direct offering of 12,000,000 shares of common stock and warrants at a combined price of $0.25, resulting in net proceeds of approximately $2.7 million. ($3.0M proceeds)

8-K filing: The Board of Directors of Citius Pharmaceuticals, Inc. approved an extension by one year to September 27, 2025, for warrants to purchase an aggregate of 2,793,297 shares of common stock with an exercise price of $0.77 per share and 194,358 warrants with an exercise price of $1.11875 per share issued in connection with the 2019 Offering were extended by one year to September 27, 2025.

8-K filing: Citius Pharma and Citius Oncology entered into an amended and restated shared services agreement, an amended and restated registration rights agreement, and a letter agreement waiving certain closing conditions of the Merger Agreement, and Citius Pharma issued a press release announcing the closing of the Merger.

10-Q filing | 173.9M shares outstanding

10-Q filing | 180.7M shares outstanding

8-K filing: Citius Pharmaceuticals, Inc. closed a registered direct offering on April 30, 2024, issuing 21,428,574 shares of common stock and warrants at a combined price of $0.70 per share, resulting in net proceeds of approximately $13.8 million. ($15.0M proceeds)

8-K filing: Citius Pharmaceuticals, Inc. approved an extension by one year to April 5, 2025 for warrants to purchase an aggregate of 1,294,498 shares of common stock, $0.001 par value per share, with an exercise price of $1.42 per share of common stock and 240,130 warrants with an exercise price of $1.9313 per share, which if fully exercised, the Company would receive approximately $2.3 million in cash proceeds.

S-3 filing: Citius Pharmaceuticals filed an S-3 registration statement on 2024-02-23, indicating a shelf offering of up to $250,000,000 of common stock, preferred stock, debt securities, warrants, rights, and units.

10-Q filing | 159.0M shares outstanding

10-K filing | 151.3M shares outstanding

10-Q filing | 153.8M shares outstanding

10-Q filing | 146.3M shares outstanding

8-K filing: Citius Pharmaceuticals, Inc. entered into a securities purchase agreement for the issuance and sale of 12,500,001 shares of common stock and warrants at a combined offering price of $1.20, closing on May 8, 2023, with gross proceeds of approximately $15 million. ($15.0M proceeds)

10-Q filing | 146.2M shares outstanding

10-K filing | 146.1M shares outstanding

10-Q filing | 146.1M shares outstanding

10-Q filing | 146.0M shares outstanding

10-Q filing | 146.0M shares outstanding

10-K filing | 146.0M shares outstanding

10-Q filing | 146.0M shares outstanding

POS AM filing: This prospectus relates to the issuance of up to 1,622,989 shares of common stock issuable upon the exercise of outstanding warrants, at an exercise price of $4.125 per share, and the issuance of 65,940 shares of common stock underlying the underwriter warrants issued by us on August 8, 2017, at an exercise price of $4.5375 per share, all of which expire on August 2, 2022.

10-Q filing | 135.5M shares outstanding

S-3 filing: Citrine is filing an S-3 to register 25,044,164 shares of common stock offered by selling stockholders, issuable upon the exercise of warrants.

S-3 filing: The filing is for a shelf registration to offer and sell up to $250,000,000 of common stock, preferred stock, debt securities, warrants, and rights, and also relates to the resale of 3,558,140 shares of common stock issuable upon exercise of warrants.

8-K filing: The company entered into a securities purchase agreement to sell 50,830,566 shares of common stock and warrants to purchase up to 25,415,283 shares at $1.505 per share and warrant, resulting in gross proceeds of approximately $76.5 million, which closed on February 19, 2021. ($153.0M proceeds)

10-Q filing | 75.0M shares outstanding

S-3 filing: This S-3 filing registers 24,265,857 shares of common stock for resale by selling stockholders, including shares issued and those issuable upon exercise of warrants. The company will not receive proceeds from the sale of these shares.

8-K filing: On January 24, 2021, the company entered into a securities purchase agreement for the sale of 15,455,960 shares of common stock and warrants to purchase 7,727,980 shares, closing the sale on January 27, 2021, with gross proceeds of approximately $20.0 million. ($20.0M proceeds)

10-K filing | 55.6M shares outstanding

10-Q filing | 46.3M shares outstanding

8-K filing: Citius Pharmaceuticals closed a firm commitment offering of 7,964,804 shares of common stock at $1.05 per share and an additional 1,194,720 shares upon full exercise of the underwriter's option, along with the issuance of warrants to purchase 641,166 shares of common stock to the underwriter. ($9.62M proceeds)

S-1 filing: This prospectus relates to the sale or other disposition from time to time of up to 4,023,530 shares of our common stock, $0.001 par value per share, issuable upon the exercise of warrants held by the selling stockholders named in this prospectus, including their transferees, pledgees, donees or successors.

8-K filing: On May 14, 2020, the company entered into a securities purchase agreement for the sale of 7,058,824 shares of common stock at $1.0625 per share and unregistered warrants to purchase up to 3,529,412 shares, closing the sales on May 18, 2020 with gross proceeds of approximately $7.5 million. ($15.0M proceeds)

10-Q filing | 38.1M shares outstanding

S-1 filing: Citrx offering of up to 6,739,580 shares of common stock issuable upon exercise of warrants.

8-K filing: Citius Pharmaceuticals, Inc. closed a warrant exercise agreement offering on February 19, 2020, issuing 4,425,098 shares of common stock and receiving gross proceeds of approximately $5.5 million. ($5.5M proceeds)

8-K filing: Citius Pharmaceuticals entered into a warrant exercise agreement with existing accredited investors to exercise warrants for 3,712,218 shares at $0.77 and 2,586,455 shares at $1.02, with gross proceeds expected to be approximately $5.5 million. ($11.0M proceeds)

10-Q filing | 30.2M shares outstanding